531 related articles for article (PubMed ID: 28803400)
1. Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.
Cypen J; Ahmad T; Testani JM; DeVore AD
Curr Heart Fail Rep; 2017 Oct; 14(5):434-443. PubMed ID: 28803400
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
3. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.
Khalid U; Wruck LM; Quibrera PM; Bozkurt B; Nambi V; Virani SS; Jneid H; Agarwal S; Chang PP; Loehr L; Basra SS; Rosamond W; Ballantyne CM; Deswal A
Int J Cardiol; 2017 Apr; 233():61-66. PubMed ID: 28185703
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.
Pandey A; Golwala H; Sheng S; DeVore AD; Hernandez AF; Bhatt DL; Heidenreich PA; Yancy CW; de Lemos JA; Fonarow GC
JAMA Cardiol; 2017 Feb; 2(2):136-145. PubMed ID: 28030747
[TBL] [Abstract][Full Text] [Related]
6. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
[TBL] [Abstract][Full Text] [Related]
7. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.
van Woerden G; Gorter TM; Westenbrink BD; Willems TP; van Veldhuisen DJ; Rienstra M
Eur J Heart Fail; 2018 Nov; 20(11):1559-1566. PubMed ID: 30070041
[TBL] [Abstract][Full Text] [Related]
8. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
9. Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: a report from the CHART-2 Study.
Kasahara S; Sakata Y; Nochioka K; Yamauchi T; Onose T; Tsuji K; Abe R; Oikawa T; Sato M; Aoyanagi H; Miura M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
Heart Vessels; 2018 Sep; 33(9):997-1007. PubMed ID: 29569034
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction.
Kleber ME; Koller L; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
Circ Heart Fail; 2015 Jan; 8(1):25-32. PubMed ID: 25342739
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
12. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
13. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
14. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
16. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction.
Winter MP; Kleber ME; Koller L; Sulzgruber P; Scharnagl H; Delgado G; Goliasch G; März W; Niessner A
Thromb Haemost; 2017 Feb; 117(3):471-478. PubMed ID: 27975104
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction.
Suzuki S; Motoki H; Minamisawa M; Okuma Y; Shoin W; Okano T; Kimura K; Ebisawa S; Okada A; Kuwahara K
Heart Vessels; 2019 Oct; 34(10):1650-1656. PubMed ID: 30929038
[TBL] [Abstract][Full Text] [Related]
19. Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review.
Garg A; Virmani D; Agrawal S; Agarwal C; Sharma A; Stefanini G; Kostis JB
Cardiology; 2017; 136(3):192-203. PubMed ID: 27784010
[TBL] [Abstract][Full Text] [Related]
20. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
